RUGA CORPORATION INDEMNIFICATION AGREEMENTIndemnification Agreement • August 3rd, 2018 • Versartis, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (the “Agreement”) is made as of October 17, 2016, by and between Ruga Corporation, a Delaware corporation (the “Company”), and Vinay Shah (“Indemnitee”).
MASTER MANUFACTURING SERVICES AGREEMENTMaster Manufacturing Services Agreement • August 3rd, 2018 • Versartis, Inc. • Pharmaceutical preparations • New York
THIS MASTER MANUFACTURING SERVICES AGREEMENT (this “Agreement”) is entered into as of July 11, 2016 (the “Effective Date”), by and between WUXI BIOLOGICS (HONG KONG) LIMITED having a principal place of business at 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China 200131 (“CMO”), and ARAVIVE BIOLOGICS, INC., having a principal place of business at 909 Fannin, Suite 2100, Houston, Texas 77010 (“Client”). CMO and Client are sometimes referred to herein individually as a “Party” and collectively as “Parties.”
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 3rd, 2018 • Versartis, Inc. • Pharmaceutical preparations • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Ruga Corporation, (“RUGA”), a corporation having a principal place of business at 550 Hamilton Avenue, Suite 220, Palo Alto CA 94301, is effective on the 25th day of January, 2012 (“Effective Date”).
LICENSE AGREEMENTLicense Agreement • August 3rd, 2018 • Versartis, Inc. • Pharmaceutical preparations
This license agreement (“Agreement”), effective as of December 1, 2017 (“Effective Date”) is entered and made by and between WuXi Biologics (Hong Kong) Limited, having an address at Suite 3701-10, 37F, Jardine Hse, 1 Connaught Place, Central Hong Kong (“WuXi Biologics”) and Aravive Biologics, Inc., having its principal place of business at 1221 McKinney Street, Suite 3200, Houston, Texas 77010 (“Licensee”).
AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 3rd, 2018 • Versartis, Inc. • Pharmaceutical preparations • California
This AMENDMENT (the Amendment”) dated as of July 26, 2012 to the EXCLUSIVE LICENSE AGREEMENT (the “License Agreement”) between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and RUGA CORPORATION (“RUGA”), a corporation having a principal place of business at 550 Hamilton Avenue, Suite 220, Palo Alto CA 94301, effective as of January 25, 2012.
ContractLicense Agreement • August 3rd, 2018 • Versartis, Inc. • Pharmaceutical preparations
Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 406 of the Securities Exchange Act of 1933, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.
AMENDMENT 09/25/2017License Agreement • August 3rd, 2018 • Versartis, Inc. • Pharmaceutical preparations
Effective the 15th day of September, 2017, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and ARAVIVE BIOLOGICS, INC. (“Aravive”), a corporation having a principal place of business at 1221 McKinney, Ste. 3200, Houston, Texas 77010, agree as follows:
Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 406 of the Securities Exchange Act of 1933, as amended. A complete copy of this document has been filed separately with the Securities...Cancer Research Grant Contract • August 3rd, 2018 • Versartis, Inc. • Pharmaceutical preparations • Texas
This CANCER RESEARCH GRANT CONTRACT (“Contract”) is by and between the Cancer Prevention and Research Institute of Texas (“CPRIT”), hereinafter referred to as the “INSTITUTE”, acting through its Chief Executive Officer, and Ruga Corporation, hereinafter referred to as the “RECIPIENT”, acting through its authorized signing official.
